Euclises Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company advancing the next generation of oral, small-molecule drugs that target COX-2 to disrupt the tumor microenvironment and kill cancer cells. Our lead molecule has been shown as monotherapy to slow tumor growth and completely regress tumors when combined with immune checkpoint inhibitors by eliminating COX-2/PGE-2 mediated tumor immune evasion. In addition, added antitumor effects have been observed with other targeted agents such as EGFR inhibitors by shutting down resistance pathways.

Our mission is to advance these new molecules in combinations with both immune checkpoint and EGFR inhibitors through clinical trials.

We believe this approach has the potential to dramatically improve the overall efficacy of current immuno-oncology therapies and EGFR inhibitors, and to expand the number of patients who benefit from these agents.

Euclises boasts a team of pharmaceutical veterans who have led development of dozens of clinical candidates and marketed drugs.